Price
Target price
€17.33
€17.33
-5.790%
-1.01
-5.790%
-
24.07.26 / Tradegate
WKN: A2PLU4 / Name: Capricor / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Capricor
sharewise wants to provide you with the best news and tools for Capricor, so we directly link to the best financial data sources.
Financials
News
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- Capricor Therapeutics says it is in active discussions with the FDA to support approval of deramiocel
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), exercised 25,000 options for common stock and immediately sold the resulting shares for a transaction value of